Enhancing NAD+ biosynthesis promotes SIRT1- and SIRT3-catalyzed reactions, improving metabolic disorders such as weight gain, insulin resistance, and dyslipidemia associated with an HFD [171]. Here, SIRT1 is linked to metabolic syndrome.